# The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

> **NCT02200354** · PHASE2 · TERMINATED · sponsor: **Kobe City General Hospital** · enrollment: 20 (actual)

## Conditions studied

- Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** pemetrexed with bevacizumab

## Key facts

- **NCT ID:** NCT02200354
- **Lead sponsor:** Kobe City General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2018-03-20
- **Final completion:** 2019-03-20
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** inclusion speed
- **Last updated:** 2019-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02200354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02200354, "The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT02200354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*